A principal stratification approach to assess the differences in prognosis between cancers caused by hormone replacement therapy and by other factors

International Journal of Biostatistics

Volumn 6, Issue 1, 2010, Pages

  Sjolander, Arvid ^a   Vansteelandt, Stijn ^b   Humphreys, Keith ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

counterfactuals; estimating equation; HRT; principal stratification; prognosis

Indexed keywords

ESTROGEN; GESTAGEN;

ARTICLE; BODY MASS; BREAST CANCER; CANCER PATIENT; CASE CONTROL STUDY; COHORT ANALYSIS; HORMONE SUBSTITUTION; HUMAN; METHODOLOGY; PRINCIPAL STRATIFICATION; PROGNOSIS; RISK; STATISTICAL ANALYSIS; STRATIFIED SAMPLE; TUMOR VOLUME; AGED; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; ESTROGEN THERAPY; FEMALE; INCIDENCE; MIDDLE AGED; RISK ASSESSMENT; STATISTICAL MODEL; SURVIVAL;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; LIKELIHOOD FUNCTIONS; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 77954377306     PISSN: 15574679     EISSN: None     Source Type: Journal    
DOI: 10.2202/1557-4679.1225     Document Type: Article

References (24)

1. Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. (2004). Inuence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial. Human Reproduction 19(3), 741-756.
2. Bang H and Robins JM. (2005). Doubly robust estimation in missing data and causal inference models. Biometrics 58, 962-973.
3. Collaborative Group on Hormonal Factors in Breast Cancer. (1997). Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350, 1047-1059.
4. Collins JA, Blake JM, Crosignani PG. (2005). Breast cancer risk with postmenopausal hormonal treatment. Human Reproduction Update 11, 545-560.
5. Easton DF, Pooley KA, Dunning AM, Pharoah DP et al. (2007). A genomewide association study identi es multiple breast cancer susceptibility loci. Nature 447, 1087-1093.
6. Frangakis CE, Rubin DB. (2002). Principal strati cation in causal inference. Biometrics 58, 21-29.
7. Galea MH, Blamey RW, Elston CE, Ellis IO. (1992). The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Research and Treatment 22, 207-219.
8. Gilbert PB, Bosch JB, Hudgens MG. (2003). Sensitivity analysis for the assessment of causal vaccine e ects on viral load in HIV vaccine trials. Biometrics 59, 531-541. Jemiai Y. Semiparametric methods for the e ect of treatment on an outcome
9. existing only in a post-randomization selected subpopulation. (2005). Ph.D. Thesis, Harvard University, Cambridge, Massachusetts.
10. Jemiai Y, Rotnitzky A, Shepherd BE, Gilbert PB. (2007). Semiparametric estimation of treatment e ects on an outcome measured after a postrandomization event occurs. Journal of the Royal Statistical Society, Series B 69, 879-901.
11. Lower EE, Blau R, Gazder P, Stahl DL. (1999). The e ect of estrogen usage on the subsequent homone receptor status of primary breast cancer. Breast Cancer Res Treat 58, 205-211.
12. Magnusson C, Baron JA, Correia N, Bergström R, Adami HO, Persson I. (1999). Breast cancer risk following long-term oestrogen- and oestrogenprogestin-replacement therapy. Int. J. Cancer 81, 339-344.
13. Million Women Study Collaborators. (2003). Breast cancer and hormonereplacement therapy in the Million Women Study. The Lancet 362(9382) 419-427.
14. Nanda K, Basitan LA, Schulz K. (2002). Hormone replacement therapy and the risk of death from breast cancer: a systematic review. American Journal of Obstetrics and Gynecology 186, 325-334.
15. Prentice RL, Pyke R. (1979). Logistic disease incidence models and casecontrol studies. Biometrika 66, 403-411.
16. Robins JM, Rotnitzky A. (2001). Comment on Inference for semiparametric models: Some questions and an answer'. Statistica Sinica 11(4), 920-936.
17. Rosenberg L. (2006). Hormone-related factors and breast cancer - studies of risk and prognosis. PhD thesis, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm.
18. Rosenberg LU, Granath F, Dickman PW, Einarsdottir K, Wedren S, Persson I, Hall P. (2008). Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Research 10:r78.
19. Shepherd BE, Gilbert PB, Jemiai Y, Rotnitzky A. (2006). Sensitivity analysis comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials. Biometrics 62, 332-342.
20. Shepherd BE, Gilbert PB, Lumley T. (2007). Sensitivity analysis comparing time-to-event outcomes existing only in a subset selected postrandomization. Journal of the American Statistical Association 102, 573-582.
21. Sjiolander A, Humphreys K, Vansteelandt S, Bellocco R, Palmgren J. (2009). Sensitivity analysis for principal stratum direct e ects, with an application to a study of physical activity and coronary heart disease. Biometrics 65, 514-520.
22. van der Laan MJ. (2008). Estimation based on case-control designs with known incidence probability. Working Paper 234. Berkley Electronic Press, Berkley.
23. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of Pathology 189(1): 129.
24. Zhang JL, Rubin DB. (2003). Estimation of causal efects via principal stratication when some outcomes are truncated by "death". Journal of Educa-tional and Behavioral Statistics 28(4), 353-368.